Cooley Advises Full-Life Technologies on $110 Million Series D Equity Financing

Why It Matters

The infusion accelerates development of precision radiotherapeutics, positioning Full-Life to capture a share of the fast‑growing oncology market, while highlighting investor confidence in Singapore’s biotech ecosystem and Cooley’s cross‑border legal expertise.

Key Takeaways

• $110M Series D brings Full-Life’s total funding to $350M
• Vivo Capital leads round; SK Biopharma joins as strategic investor
• Funding targets clinical-stage assets and manufacturing scale‑up
• Cooley has advised all prior financing rounds and a $245M acquisition
• Singapore biotech gains momentum in global radiotherapy market

Pulse Analysis

Full-Life Technologies, founded in 2021, has rapidly emerged as a leading developer of fully integrated radiotherapeutics that combine diagnostic imaging with targeted radiation delivery. The recent $110 million Series D round lifts the company’s cumulative capital to roughly $350 million, a level that enables it to advance multiple clinical‑stage candidates through Phase I/II trials and to expand its GMP‑grade manufacturing facilities. In a market where precision oncology is projected to exceed $100 billion by 2030, the infusion of capital positions Full‑Life to capture a sizable share of the next generation of tumor‑specific treatments.

The financing was spearheaded by Vivo Capital, a firm with a track record of backing innovative biotech, and included strategic participation from South Korea’s SK Biopharmaceuticals. Their involvement not only validates Full‑Life’s scientific platform but also opens distribution channels across Asia‑Pacific. Additional investors such as Chengwei Capital and Sky9 Capital broaden the company’s network of industry expertise, which can accelerate regulatory approvals and commercial partnerships. For Singapore’s biotech sector, the deal reinforces the city‑state’s reputation as a hub for high‑value, cross‑border life‑science investments.

Cooley LLP served as legal counsel, a role it has held through Full‑Life’s earlier Series A, B, C rounds and a $245 million acquisition of Focus‑X Therapeutics. Navigating multi‑jurisdictional securities regulations, intellectual‑property licensing, and merger‑related due diligence requires a firm with deep cross‑border capabilities, which Cooley provides through its 1,400‑lawyer global platform. The firm’s continued partnership signals confidence in Full‑Life’s growth trajectory and highlights the importance of sophisticated legal infrastructure in scaling biotech ventures from early‑stage financing to global commercialization.